Skip to main content

BHVN

Stock
Health Care
Biotechnology

Performance overview

BHVN Price
Price Chart

Forward-looking statistics

Beta
1.50
Risk
63.46%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Company info

SectorHealth Care
IndustryBiotechnology
Employees239
Market cap$3.0B

Fundamentals

Enterprise value$1.2B
Revenue$0.0
Revenue per employee—
Profit margin0.00%
Debt to equity13.69

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)-$9.25
Dividend per share—
Revenue per share$0.00
Avg trading volume (30 day)$27M
Avg trading volume (10 day)$27M
Put-call ratio—

Macro factor sensitivity

Growth-0.1
Credit+4.7
Liquidity-0.5
Inflation-3.6
Commodities+0.7
Interest Rates-4.2

Valuation

Dividend yield0.00%
PEG Ratio-2.31
Price to sales—
P/E Ratio-2.31
Enterprise Value to Revenue—
Price to book5.76

Upcoming events

Next earnings dayMarch 3, 2025
Next dividend day—
Ex. dividend day—

News

Why Is Biohaven Stock Falling On Thursday?

Biohaven Ltd. BHVN shares plunged on Thursday after the Food and Drug Administration (FDA) unexpectedly delayed the review date for its rare-disease drug troriluzole.

Benzinga (May 15, 2025)
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal

The pivotal BHV4157-206-RWE study evaluating Biohaven's pipeline candidate, troriluzole, for treating spinocerebellar ataxia meets its primary endpoint.

Zacks Investment Research (September 24, 2024)
How Biohaven's experimental obesity drug could prevent muscle loss

Vlad Coric, Biohaven CEO, joins 'Fast Money' to discuss the weight loss drug wars and the company's experimental obesity drug.

CNBC Television (March 25, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free